His main research concerns Melanoma, Cancer research, Internal medicine, Vemurafenib and Oncology. The study incorporates disciplines such as Survival rate, V600E, Ipilimumab and Hazard ratio in addition to Melanoma. His Cancer research research incorporates elements of Mutation, Carcinogenesis, Neuroblastoma RAS viral oncogene homolog, Cell cycle and PTEN.
His biological study spans a wide range of topics, including Gastroenterology and Surgery. His research in Vemurafenib intersects with topics in Proto-Oncogene Proteins B-raf, Mutant and Drug resistance. His studies deal with areas such as Clinical endpoint, Trametinib, Imatinib, Pharmacology and Immunotherapy as well as Oncology.
Melanoma, Cancer research, Internal medicine, Oncology and Vemurafenib are his primary areas of study. His Melanoma research includes elements of Cancer, Targeted therapy, Immunology and Neuroblastoma RAS viral oncogene homolog. His Cancer research study incorporates themes from Protein kinase B, Kinase, Cell cycle, PI3K/AKT/mTOR pathway and Transcription.
As part of his studies on Internal medicine, Grant A. McArthur often connects relevant areas like Surgery. His Oncology research is multidisciplinary, relying on both Metastatic melanoma, Pathology, Placebo, Hazard ratio and Immunotherapy. His work deals with themes such as V600E, MEK inhibitor and Dacarbazine, which intersect with Vemurafenib.
Grant A. McArthur mainly focuses on Melanoma, Internal medicine, Cancer research, Oncology and Vemurafenib. Grant A. McArthur has researched Melanoma in several fields, including Cancer, Targeted therapy, Immunotherapy, MEK inhibitor and Neuroblastoma RAS viral oncogene homolog. When carried out as part of a general Internal medicine research project, his work on Ipilimumab, Clinical trial, Cohort and Hazard ratio is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Cancer research research integrates issues from Protein kinase B, Oncogene, Ribosome biogenesis, Translation and Transcription. The Oncology study combines topics in areas such as Metastatic melanoma, Retrospective cohort study, Biomarker, Prospective cohort study and Adjuvant therapy. His Vemurafenib research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Survival analysis and Dacarbazine.
Grant A. McArthur mostly deals with Melanoma, Internal medicine, Cancer research, Oncology and Vemurafenib. He studies Dabrafenib which is a part of Melanoma. His Cancer research research incorporates themes from Oncogene, Cyclin-dependent kinase 6, Palbociclib and Cyclin-dependent kinase 4.
He has included themes like Systemic therapy and Adjuvant therapy in his Oncology study. The concepts of his Vemurafenib study are interwoven with issues in MEK inhibitor and Medical imaging. His Ipilimumab study combines topics in areas such as Nivolumab and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen.
The New England Journal of Medicine (2011)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob.
The New England Journal of Medicine (2015)
Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas.
The New England Journal of Medicine (2010)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski.
The New England Journal of Medicine (2017)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein.
The Lancet (2006)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong.
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez.
The New England Journal of Medicine (2012)
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine
J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob.
The New England Journal of Medicine (2019)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson.
The New England Journal of Medicine (2014)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: